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Human internal anal sphincter (IAS) is contracted by a1-adrenoceptor stimulation and thus a1-adreno-
ceptor agonists may be useful in treating fecal incontinence. This study characterizes the contribution of
a1-adrenoceptor subtypes in contraction of human IAS and to investigate the age-related risk of patients
with fecal incontinence. IAS and inferior mesenteric artery (IMA), as a predictor of systemic arterial
pressure, were obtained from 11 patients. Both muscle strips were assessed by isometric-contraction
experiments using phenylephrine, further in IAS, in the presence of various subtype selective a1-adre-
noceptor antagonists. Immunohistochemistry and gene expression studies were performed in the same
samples. The mean pEC50 values with SEM of phenylephrine in IAS (6.30 ± 0.13) were higher than those
of IMA (5.60 ± 0.10). Furthermore, the age-related pEC50 change of IAS was observed between age <70
and 70 (6.58 ± 0.13 and 6.07 ± 0.16, respectively (P < 0.05)). In IAS, rightward shift of the concentration
eresponse curves of phenylephrine was observed with three a1-adrenoceptor antagonists. Each pKB
value of silodosin, BMY-7378 and prazosin was 9.36 ± 0.53, 7.28 ± 0.20 and 8.89 ± 0.12, respectively.
These pKB values and gene expression studies indicated that a1A-adrenoceptor subtypes predominantly
contributed to human IAS contraction.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Passive fecal incontinence is deﬁned as the involuntary loss of
solid or liquid feces. It is a common symptom that causes signiﬁcant
distress and reduces quality of life, with a prevalence of 1.6%e15.3%
(1). Passive fecal incontinence is caused by contractile dysfunction
of the internal anal sphincter (IAS), which is located in the distal
end of the rectum and composed of concentric layers of circular
muscle tissue under involuntary control (2e4). This circular smooth
muscle has an important role inmaintainingmaximum anal resting
pressure (MRP) (5). Its contraction occurs through sympathetic
nerve stimulation (6e9).
Since the 1990s, several clinical trials for pharmaceutical treat-
ment of passive fecal incontinence have been conducted (10e14).nferior mesenteric artery.
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d/4.0/).Alpha1-adrenoceptor agonists, phenylephrine and noradrenaline
were tested, because it is well known to produce contractile
response in human IAS in vitro (15, 16). In addition, topical drug
administration around the anus were performed to avoid the
common adverse effects; elevation of systemic blood pressure. In
these studies, the administration of 30% (w/w) phenylephrine gel to
the distal anal canal markedly increased MRP in patients with
passive fecal incontinence but also elevated the systemic blood
pressure (12). Further, topical administration of an a1A-adreno-
ceptor agonist, L-erythro-methoxamine was characterized with
higher a1A-adrenoceptor activity than phenylephrine. L-erythro-
methoxamine 3% (w/w) gel applied to the anal canal or rectum of
healthy volunteers not only increased MRP for 5 h but also elevated
systemic blood pressure in some healthy volunteers (17). Therefore,
they adopted the lower concentrations, 0.3% or 1% (w/w) of L-
erythro-methoxamine gel in patients with passive fecal inconti-
nence. However, not only did the dose increase MRP for 2 h but also
elevate systemic blood pressure (18). To date, there are no suc-
cessful clinical reports using a topical a1-adrenoceptor agonist
without elevating blood pressure.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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ied in IAS smooth muscle of pig (19, 20) and sheep (21); a1A/L-
adrenoceptor contracted it in the pig (20), whereas the a1A- and
a2D-adrenoceptors contracted it in the sheep (21). However, there is
no reliable information concerning a1-adrenoceptor subtypes in
human IAS. The ﬁrst aim of the current study was to characterize
the contribution of a1-adrenoceptor subtypes in contraction of the
human IAS; and the second aim was to investigate the epidemio-
logical risk factors of patients with fecal incontinence.
2. Materials and methods
2.1. Ethical approval
Approval for the study was obtained from the Institutional Re-
view Board for Clinical Research of Tokai University Hospital
(No.09R153 and 08R033) and conducted in compliance with the
ethical guidelines of clinical research in the implementation plan.
2.2. Patients
All patients provided written informed consent before partici-
pation. Specimens were obtained from 11 patients [8 males, 3 fe-
males; median age 70 (range 36e86) years old] that underwent
abdominoperineal resection during the period from May to
December in 2010 in Tokai University Hospital. The following
anonymized patient information was obtained: race, age, gender,
number of vaginal deliveries (if female), and the presence or
absence of fecal incontinence symptoms. All patients had locally
advanced rectal carcinoma, were Japanese, and presented with no
symptoms of fecal incontinence at surgery. The vaginal deliveries
frequency of patient case No.5, 6 and 8 were 1, 2 and 3 experiences,
respectively. The Case No.4e11 patients received 40e45 Gy
radiation.
2.3. Isometric contraction experiments
The fresh tissues including part of the IAS and inferior mesen-
teric artery (IMA) were obtained from the sites those were not
affected by prior radiological treatment, which was conﬁrmed by
HE staining. The tissue was placed in ice-cold modiﬁed Krebs buffer
gassed with 5% CO2 in oxygen within 15 min of resection in oper-
ating room. The following procedure was started within an hour of
the resection. Surrounding mucosa, submucosa, connective tissue
and external-anal sphincter were removed from the tissues, and
IAS and IMAwere isolated. The IAS was dissected in the direction of
the smooth muscle bundles. The IMA was dissected in the helical
direction and its endotheliumwas removed. The IAS and IMAwere
cut into 12 mm  3 mm strips. Three or more strips were obtained
from individual tissues.
Strips were vertically placed in 10-mL organ baths containing a
modiﬁed Krebs buffer at 37 C and gassed with 5% CO2 in oxygen.
One end of each strip was connected to a force-displacement
transducer (SB-1T, NIHON KOHDEN, Tokyo, Japan), and changes in
muscle tension were measured and recorded on a pen-writing
oscillograph (Rectigraph 8S, NEC-Sanei, Tokyo, Japan). The prepa-
rations were allowed to equilibrate with 10 mN of resting tension
for at least 30 min at each 10 min interval wash out before starting
the experiments. Strips were then stimulated with 0.1 mM phen-
ylephrine and their contractile response was conﬁrmed. After the
conﬁrmation, strips were immediately washed and allowed to
equilibrate for at least 30 min until the tension returned to its base
value.
The concentrationeresponse curves were obtained by the cu-
mulative addition of 1 nM to 1 mM of phenylephrine to the bathingsolution. After attaining the successive concentrationeresponse
curves for phenylephrine, IAS strips were immediately washed and
allowed to equilibrate both with and without a1-adrenoceptor
antagonists. The following antagonists were used: the selective
a1A-adrenoceptor antagonist, silodosin (3 nM); the selective a1D-
adrenoceptor antagonist, BMY-7378 (3 mM) and the non-subtype-
selective a1-adrenoceptor antagonist, prazosin (25 nM). Each
preparationwas equilibrated with the antagonist for 30 min before
the next addition of phenylephrine in the manner described above.
Only one concentrationeresponse curve was obtained from each
strip. Maximum contraction of strip was conﬁrmed by application
to 40 mM KCl at the end of experiment. The contractile responses
were expressed in mN, and as a percentage of the maximum
response for each concentrationeresponse curve [expressed as
mean ± standard error of the mean (SEM)].
Individual concentrations producing 50% maximal response
(pEC50 values) were calculated by non-linear regression ﬁtting to
sigmoidal concentrationeresponse curves (variable slope) by
GraphPad Prism® software version 4 (GraphPad Software Inc, San
Diego, USA). Individual afﬁnity estimates (apparent pKB values)
were determined from the equation: {pKB ¼ [log (EC50 without
antagonist/EC50 with antagonist)  1]  log (antagonist concen-
tration)}. The data are reported as mean ± SEM. Statistical signiﬁ-
cance of experimental observations is determined by the Student's
t-test with the level of signiﬁcance set at P < 0.05.
This study was limited by the relatively small number of pa-
tients, because it was difﬁcult to obtain human tissues for labora-
tory studies, and could not use more concentrations of antagonists
for calculate to pA2 value.
2.4. Quantitative polymerase chain reaction
The IAS tissues were obtained before organ bath technique and
stored in All-prep reagent® (Qiagen, USA) at  20 C. Total RNA
samples were extracted using the RNeasy® kit (Qiagen) according
to manufacturer instructions. These total RNA samples used for
following both of quantitative polymerase chain reactions (PCR).
Pre-designed primer sets, Perfect Real-Time™ primer (Takara Bio
Inc, Otsu, Japan), were used for three genes, including a1A-adre-
noceptor (ID: HA073254), a1B-adrenoceptor (ID: HA032618), a1D-
adrenoceptor (ID: HA093200). Quantitative PCRwas performed in a
25-mL reaction volume using the SYBR® Premix Ex Taq™ kit (Takara
Bio Inc). Complementary DNA (equivalent to 10 ng of total RNA)
was synthesized using Super-Script II reverse transcriptase (Life
Technologies, Tokyo, Japan) and mixed with Taq Universal Mix
(Applied Biosystems, Tokyo, Japan), 0.3-mM primer sets and 0.3-mM
TaqMan probe. Quantitative PCR was performed using DNA Engine
Opticon (MJ Research, Cambridge, USA) as follows: 1  10 min at
95 C, 40 cycles of denaturation (15 s at 95 C) and annealing/
extension (1 min at 60 C). The exact copy number was determined
by a standard curve of complementary DNA for each gene of
plasmid DNA templates and shown as the number of transcripts per
1 ng total RNA equivalent. The data are reported as mean ± SEM.
Statistical signiﬁcance of the experimental observations was
determined by one-way analysis of variance (ANOVA) and Dun-
nett's post-hoc multiple comparison test, with the level of signiﬁ-
cance set at P < 0.05.
2.5. Immunohistochemical observations
Tissues were ﬁxed in Bouin's solution and were embedded in
parafﬁn wax. After removing parafﬁn wax, sections (5 mm) were
incubated in phosphateebuffered saline (PBS) containing 2%
bovine serum albumin (BSA) with gentle agitation overnight at
4 C. Sections were washed ﬁve times for 5 min each with PBS,
Fig. 1. Concentrationeresponse curves for phenylephrine (1 nMe1 mM) in the smooth
muscle strips from elderly and younger patients. A, the elderly subgroup (age  70;
n ¼ 26 strips from 6 patients; triangle) and the younger subgroup (age < 70; n ¼ 23
strips from 6 patients; circle) in internal anal sphincter (IAS). B, the elderly subgroup
(age  70; n ¼ 20 strips from 5 patients; triangle) and the younger subgroup (age < 70;
n ¼ 19 strips from 5 patients; circle) in inferior mesenteric artery (IMA). Data show the
mean ± SEM. Statistical signiﬁcance between two concentration-response curves was
determined by the Student's paired t-test after repeated measured ANOVA. Some
points in concentrationeresponse curves of the elderly are signiﬁcantly higher
compared with that of the younger in IAS (*P < 0.05).
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mary polyclonal antibodies, including the a1A-, a1B- and a1D-adre-
noceptors (diluted 1:500 in PBS) for 60 min at room temperature.
The sections were washed ﬁve times (5 min each) with PBS and
then washed once with 2% BSAePBS, and incubated with Biotin-
labelled goat anti-rabbit IgG secondary antibody (diluted 1:200 in
PBS) for 30 min at room temperature. The sections were washed
ﬁve times with PBS and subjected to immunohistochemical anal-
ysis. Polyclonal antibodies to human a1A-, a1B- and a1D-adreno-
ceptors and secondary antibody (Acris Antibodies, Hiddenhausen,
Germany) were obtained from Funakoshi Inc (Tokyo, Japan).
2.6. Drugs and solutions
Silodosin was obtained from Funakoshi Inc and phenylephrine,
BMY-7378 and prazosin were obtained from SigmaeAldrich Co LLC
(Tokyo, Japan). All drugs were dissolved and serially diluted in sa-
line. The composition of the modiﬁed Krebs buffer was (in mM):
NaCl 119.0, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25.0
and glucose 11.1. Reagents were obtained from Nacalai tesque
(Tokyo, Japan).
3. Results
3.1. Phenylephrine-induced contraction in human IAS and IMA
smooth muscle
As expected, phenylephrine produced concen-
trationedependent contractile responses in both IAS and IMA
(Fig. 1A and B). The mean pEC50 values with SEM for IAS and IMA
were 6.30 ± 0.13 and 5.60 ± 0.10, respectively (Table 1), indicating
that the effect of phenylephrine on the IAS contraction was more
potent than that of the IMA (P < 0.05). It was also shown in the
younger group (6.58 ± 0.13 vs 5.60 ± 0.13, P < 0.05). In addition,
pEC50 values for 23 IAS-strips in the younger group (age < 70; n¼ 5
patients; 6.58 ± 0.13) were signiﬁcantly higher than those for 26
IAS-strips in the elderly group (age  70; n ¼ 6 patients;
6.07 ± 0.16) (P < 0.05) (Table 1, Fig. 1A). On the other hand, there
was no signiﬁcant difference in pEC50 values between the two
groups in IMA (Table 1, Fig. 1B).
3.2. Effects of antagonists on phenylephrine-induced contraction in
human IAS smooth muscle
All of the a1-adrenoceptor antagonists shifted the
phenylephrine-induced contraction curve to the right in human
IAS. But the maximum responses were altered by neither of all
antagonists. These pEC50 values of the shifted curve with antago-
nists were signiﬁcantly changed from pEC50 value without antag-
onists (P < 0.05). Each mean pKB value was calculated and listed
with the published pKB (pA2) values in Table 2.
3.3. Immunohistochemical observations
The IAS smooth muscle was positively and strongly stained by
the a1A- and a1D-adrenoceptors, but was weakly stained by a1B-
adrenoceptor (Fig. 2). Moreover, peripheral nerve bundles were
stained by the a1A-adrenoceptor and blood vessel intimal smooth
muscle was stained by the a1D-adrenoceptor.
3.4. Gene expression levels of a1-adrenoceptor subtypes in IAS
The mRNA expressions of a1-adrenoceptor subtypes were
conﬁrmed by quantitative PCR (Fig. 3A). The gene expression of
a1A- and a1D-adrenoceptors in IAS was not different but that of a1B-adrenoceptor was negligible (P < 0.05). In addition, each gene
expression of the a1A-adrenoceptor and a1D-adrenoceptor was
approximately 1.9-fold and 1.4-fold higher in the elderly group
compared with that in the younger group, although there were no
signiﬁcant differences between them (Fig. 3B, C).4. Discussion
General risk factors for passive fecal incontinence include old
age, female gender, high frequency vaginal delivery (1) and long
term radiation therapy (13, 22). In particular, the prevalence rate of
fecal incontinence increases with age in both males and females;
the prevalence in those aged >60 years (23, 24) or >70 years (1) has
been shown to be signiﬁcantly higher compared with that in
younger persons. Passive fecal incontinence is frequently caused by
contractile dysfunction of IAS, which is contracted by a1-adreno-
ceptor stimulation. To the best of our knowledge, no reliable
Table 1
Patient information and each of EC50 value for phenylephrine in human internal anal sphincter (IAS) and inferior mesenteric artery (IMA) smooth muscles.
Case no. Gender Age
(y)
IAS pEC50 IAS maximum response
(mN)
IMA pEC50 IMA maximum response
(mN)
Elderly group (70)
1 M 70 5.85 16.64 e e
3 M 73 5.55 8.65 5.03 20.99
5 F 70 6.12 3.88 5.52 10.81
6 F 80 5.86 7.11 6.05 12.01
7 M 72 6.66 16.27 5.79 30.79
8 F 87 6.37 33.08 5.56 20.45
Younger group (<70)
2 M 60 6.23 3.55 5.88 5.63
4 M 57 6.38 10.64 5.23 25.06
9 M 69 6.77 8.87 5.56 13.12
10 M 36 6.58 5.37 5.91 15.03
11 M 60 6.96 27.44 5.44 24.97
Mean Mean with SEM
Total case 66.7 6.30 ± 0.13* 12.86 ± 2.93 5.60 ± 0.10 17.89 ± 2.47
Elderly group (70) 75.3 6.07 ± 0.16y 14.27 ± 4.30 5.59 ± 0.17 19.01 ± 3.61
Younger group (<70) 56.4 6.58 ± 0.13z 11.17 ± 4.25 5.60 ± 0.13 16.76 ± 3.72
The upper part; All patients were divided into two groups by age. Data show the mean pEC50 of 3e6 smooth muscle strips. The lower part; Data show the mean of age and
mean ± SEM of pEC50. Student's paired t-test. *P < 0.05 vs IMA pEC50 of total case. yP < 0.05 vs IAS pEC50 of the Elderly group. zP < 0.05 vs IMA pEC50 of the younger group.
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been reported; however, topical anal treatment with a1-adreno-
ceptor agonists has been used to locally contract IAS, while aiming
not to elevate systemic blood pressure (12, 17, 18).
4.1. Individual difference and age-related responsiveness change in
human IAS and IMA
In the present study, IAS from 11 patients, with no symptoms of
fecal incontinence, contracted in a concentrationedependent
manner when exposed to an a1A-adrenoceptor agonist. Previous
reports using noradrenaline and phenylephrine in IAS of healthy
volunteers showed similar contractions, although there was no
information about a1-adrenoceptor subtypes (15, 16, 25).
Marked individual differences in pEC50 values were observed
between IAS and IMA because patient conditions were different
among individuals; for example, age [6 patients aged 70 years, 5
patients aged <70 years (median age 70 years)], gender, number of
vaginal deliveries, and radiation therapy. Nevertheless, a signiﬁ-
cantly higher pEC50 value of IAS for phenylephrine than that of IMA
was observed. This result suggested the possibility of differenti-
ating effects of a1-adrenoceptor agonist, phenylephrine on IAS
compared with that on IMA according to patient conditions.
The pEC50 values of phenylephrine for IAS in the younger group
were signiﬁcantly higher than those in the elderly group (see
Table 1). Furthermore, IAS sensitivity to phenylephrine was more
potent than IMA in the younger group. Accordingly, phenylephrine
could be a more effective therapy for fecal incontinence in the
younger group. Although most patients with fecal incontinence areTable 2
Afﬁnity values of various antagonists of a1-adrenoceptor in human internal anal
sphincter (IAS) smooth muscles.
Antagonist Published pKB (pA2) values and
SEM of a1-adorenoceptor subtypes
Mean pKB values
and SEM
a1A a1B a1D
Silodosin 9.86 ± 0.32 7.52 ± 0.30 8.56 ± 0.45 9.36 ± 0.53
BMY-7378 6.30 ± 0.15 6.93 ± 0.25 8.80 ± 0.60 7.28 ± 0.20
Prazosin 9.20 ± 0.29 9.60 ± 0.14 9.50 ± 0.06 8.89 ± 0.12
Published pKB (pA2) values obtained from functional and binding studies (27e33).
Mean pKB values with SEM for antagonists obtained using phenylephrine as the
agonist in human IAS (n ¼ 8e9).
Fig. 2. Immunohistochemical analysis by staining with anti-a1A-, anti-a1B- and anti-
a1D- adrenoceptor antibodies in the human internal anal sphincter (IAS) at high
magniﬁcation. Positive stain is brown. The IAS smooth muscle was positively
and strongly stained by the a1A- and a1D-adrenoceptors, but was weakly stained by
a1B-adrenoceptor. Peripheral nerve bundles were stained by the a1A-adrenoceptor (an
arrow head in A) and blood vessel intimal smooth muscle was stained by the a1D-
adrenoceptor (an arrow in C). Scale bar ¼ 100 mm.
Fig. 3. Expression of a1-adrenoceptor subtypes mRNA in the human internal anal
sphincter (IAS). The data is shown in copy numbers per 1 ng complementary DNA
(cDNA). A; The data show the mean ± SEM of 11 observations. B; The data show the
mean ± SEM of elderly group (n ¼ 6). C; The data show the mean ± SEM of younger
group (n ¼ 5). Statistical signiﬁcance between each subtype was determined by one-
way analysis of variance (ANOVA) and Dunnett's post-hoc multiple comparison test.
The expression of the a1B-adrenoceptor is signiﬁcantly lower compared with that of
the a1A- and a1D-adrenoceptors (*P < 0.05).
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patients.
Each gene expression for the a1A-adrenoceptor and a1D-adre-
noceptor in IAS of the elderly group was relatively high compared
to that of the younger group (Fig. 3). However, the contraction of
IAS in the elderly was weaker compared with that in the younger
group (Table 1). These results suggest the possibility that reduced
muscle reactivity to endogenous agonists in the elderly may result
in fecal incontinence. In addition, it seems likely that the up-
regulation of a1A-adrenoceptor and a1D-adrenoceptor gene ex-
pressions with age is not linked to the contractile function of the
IAS. However, this up-regulation may be a compensatory increase
in receptor gene expression caused by the decrease in reactivity.
4.2. Distribution of a1-adrenoceptor subtypes in human IAS
The immunoreactivities for a1A-adrenoceptor and a1D-adreno-
ceptor were potent and that for a1B-adrenoceptor was weak (Fig. 2).
The gene expressions of a1A-adrenoceptor and a1D-adrenoceptor
subtypes were higher than that of a1B-adrenoceptor subtype, sug-
gesting the absence of a1B-adrenoceptor in human IAS (Fig. 3A).
However, in the expression of each a1-adrenoceptors may change
age-dependently due to different gene expression ratios between
both receptors (see Fig. 3B, C).
The pKB value of silodosin was ranked between each published
pKB value of a1A-adrenoceptor and a1D-adrenoceptor. In the pKB
value of BMY-7378 is 30-fold (1.5 log units) below its afﬁnity at a1D-
adrenoceptors in IAS (Table 2). On the other hand, the intermediate
afﬁnity obtained for prazosin are mediated via the a1A -adreno-
ceptor but it is not possible to determine whether it is the high or
lowafﬁnity state of this receptor that exists in the human IAS. These
results suggest the possibility that a1A-adrenoceptor contribute to
contraction of human IAS. This possibility is supported by previous
study showing that in the human urethra, the a1-adrenoceptor
subtype a1A have been reported to contribute to smooth muscle
contraction (34).
The IAS contraction is reported to be mediated by a1A- and a1D-
adrenoceptor in the sheep (21) and by a1A/L-adrenoceptor in the pig
(20). Thus, inter-species differences may exist in the receptor sub-
types contribute to the contraction of the IAS between human and
other larger mammals.
A previous study using the same approach as the present study
suggested the possibility that the contraction of most arteries,
including the carotid, femoral and mesenteric arteries is mediated
by the a1A-adrenoceptor (26). The results presented here indicate
that increased systemic blood pressure may not be avoided by
increasing the receptor selectivity. At present, some topical drugs
those applied to anal area are developed to improve fecal inconti-
nence. Although these drugs are applied directly to IAS and increase
anal pressure, they are ultimately absorbed into the systemic cir-
culation, resulting in detrimental elevation of systemic arterial
blood pressure.
In clinical settings, any topically applied drugs with higher a1A-
adrenoceptor selectivity and higher activity than phenylephrine
(19, 20) were also absorbed into the systemic circulation, resulting
in elevated blood pressure (17, 18). These results suggest that top-
ically administered drugs of a1A-adrenoceptor agonists require
some strategies preventing from the absorbance into the systemic
circulation.
5. Conclusion
To the best of our knowledge this study is the ﬁrst report on the
differential effects of a1-adrenoceptor subtypes in contracting the
human IAS, and to reveal the corresponding gene expression levels
H. Owaki et al. / Journal of Pharmacological Sciences 127 (2015) 424e429 429in detail. In addition, we examined the epidemiological risk factors
of patients with fecal incontinence. This is an unpleasant disease
that reduces the quality of life and dignity of sufferers in spite of
ageing-related common symptoms. However, there remains the
risk of systemic side effects such as elevated blood pressure, which
seems particularly likely in the elderly. Treatment of fecal inconti-
nence with a1-adrenoceptor agonists requires a strategy to mini-
mize the risk of elevated blood pressure among elder patients.
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